Its sad that we have medications that could work or could save lives and the individuals who could benefit the most cant have access to this because of barriers that exist, Stewart said
Again, orforglipron is still being studied and in late clinical trials, but heres the expected timeline: Eli Lilly plans to submit it to the FDA in late 2025 for approval for weight loss in adults with a BMI of 30 or higher, or 27 and higher with a related health condition
Phase 3 SYNCHRONIZE trials for obesity are fully enrolled with results expected H1 2026
In A-treated astrocytes, GLP-1 prevented mitochondrial fragmentation, and improved the neuronal supportive ability via cAMP/PKA pathway (188)
Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial
Newer Glucagon-Like Peptide-1 receptor agonists are associated with improved glycemic control in US adults with type 2 diabetes: A Population-Level time series analysis